Rigel Pharmaceuticals
RIGL
47.69
-0.31
-0.64%
Rigel Pharmaceuticals
US · RIGL
#3318 by market cap
47.69
-0.31
-0.64%
Live - 5344 symbols - heartbeat 291s ago
· 2026-10-08 09:53
After-hours
47.00
-2.06%
- Market cap
- 890.75M
- P/E (TTM)i
- 2.82
- P/Bi
- 2.09
- EPSi
- 19.48
- Div yieldi
- 0.00%
- 52W posi
- 83%
Reader sentiment
Are you bullish or bearish on RIGL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.30, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +64.15% YoY
Margins
- Gross margin
- 93.33%
- Operating margin
- 42.63%
- Net margin
- 124.72%
Key ratios & quality
- Enterprise valuei
- 788.70M
- Altman Z-Scorei
- 3.30
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 44.51M | 59.29M | 108.62M | 149.24M | 120.24M | 116.88M | 179.28M | 294.28M |
| Gross profit | 44.22M | 58.38M | 107.73M | 148.15M | 118.49M | 109.77M | 160.63M | 274.66M |
| Selling & admin expenses | 70.00M | 74.59M | 76.60M | 91.89M | 112.45M | 105.74M | 113.06M | 115.90M |
| Research & development | 46.90M | 52.89M | 60.10M | 65.24M | 60.27M | 24.52M | 23.38M | 33.30M |
| Operating profit | -72.68M | -69.09M | -28.97M | -8.98M | -54.23M | -20.49M | 24.19M | 125.47M |
| Pretax profit | -70.48M | -66.89M | -29.74M | -17.31M | -58.57M | -25.09M | 18.37M | 121.83M |
| Tax | -- | 0 | 0 | 605.00K | 0 | 0 | 881.00K | -245.20M |
| Net profit | -70.48M | -66.89M | -29.74M | -17.91M | -58.57M | -25.09M | 17.49M | 367.02M |
| Basic EPS | -4 | -4 | -2 | -1 | -3 | -1 | 1 | 20 |
| Diluted EPS | -4.40 | -4.00 | -1.80 | -1.10 | -3.44 | -1.44 | 0.99 | 19.48 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 53.33M | 101.69M | 69.46M | 69.80M | 58.82M | 78.70M |
| Gross profit | 48.92M | 97.18M | 64.71M | 63.85M | 54.21M | 70.18M |
| Selling & admin expenses | 27.72M | 29.26M | 28.94M | 29.99M | 30.65M | 32.64M |
| Research & development | 8.44M | 6.82M | 7.35M | 10.69M | 11.68M | 13.96M |
| Operating profit | 12.77M | 61.10M | 28.42M | 23.17M | 11.89M | 23.58M |
| Pretax profit | 11.51M | 59.98M | 27.62M | 22.71M | 11.66M | 23.59M |
| Tax | 65.00K | 369.00K | -280.00K | -245.35M | 3.00M | 6.30M |
| Net profit | 11.45M | 59.61M | 27.90M | 268.07M | 8.65M | 17.29M |
| Basic EPS | 1 | 3 | 2 | 15 | 0 | 1 |
| Diluted EPS | 0.63 | 3.28 | 1.46 | 13.54 | 0.44 | 0.88 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 136.99M | 119.01M | 88.98M | 154.47M | 115.90M | 99.27M | 135.10M | 240.17M |
| Cash & ST investments | 128.54M | 98.08M | 57.33M | 124.97M | 58.21M | 56.93M | 77.32M | 154.96M |
| Inventory | 894.00K | 1.35M | 1.64M | 6.62M | 9.12M | 5.52M | 6.00M | 11.51M |
| Total assets | 139.11M | 147.57M | 110.38M | 167.33M | 134.28M | 117.23M | 163.98M | 513.59M |
| Total current liabilities | 27.73M | 58.21M | 40.84M | 63.55M | 65.21M | 53.27M | 63.30M | 99.24M |
| Short-term debt | -- | 7.27M | 8.62M | 9.89M | 1.13M | 7.92M | 7.56M | 30.43M |
| Long-term debt | -- | 9.81M | 19.82M | 19.91M | 39.45M | 52.37M | 52.41M | 22.48M |
| Total liabilities | 29,232,000.00 | 93,754,000.00 | 76,352,000.00 | 136,954,000.00 | 147,895,000.00 | 145,869,000.00 | 160,688,000.00 | 122,114,000.00 |
| Total equity | 109.88M | 53.82M | 34.03M | 30.37M | -13.62M | -28.64M | 3.29M | 391.48M |
| Retained earnings | -1.21B | -1.28B | -1.31B | -1.32B | -1.38B | -1.41B | -1.39B | -1.02B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 146.56M | 175.39M | 214.93M | 240.17M | 234.03M | 185.53M |
| Cash & ST investments | 77.10M | 108.38M | 137.14M | 154.96M | 146.68M | 95.33M |
| Inventory | 4.66M | 10.42M | 13.30M | 11.51M | 11.65M | 14.37M |
| Total assets | 175.97M | 206.74M | 242.53M | 513.59M | 504.61M | 521.07M |
| Total current liabilities | 66.63M | 86.64M | 94.40M | 99.24M | 89.49M | 95.59M |
| Short-term debt | 15.27M | 22.88M | 30.36M | 30.43M | 30.50M | 39.89M |
| Long-term debt | 44.93M | 37.45M | 29.97M | 22.48M | 14.99M | -- |
| Total liabilities | 157,405,000.00 | 124,802,000.00 | 124,925,000.00 | 122,114,000.00 | 104,711,000.00 | 95,644,000.00 |
| Total equity | 18.57M | 81.93M | 117.61M | 391.48M | 399.90M | 425.42M |
| Retained earnings | -1.38B | -1.32B | -1.29B | -1.02B | -1.01B | -997.10M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -58.83M | -41.51M | -52.19M | 5.88M | -73.76M | -5.74M | 31.47M | 75.66M |
| Depreciation & amortization | 594.00K | 683.00K | 706.00K | 1.16M | 998.00K | 1.24M | 2.23M | 2.42M |
| Free cash flow | -59.93M | -42.97M | -53.45M | 5.25M | -74.21M | -20.74M | 31.08M | 75.66M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 67.16M | -- | -- | -- | 0 | 0 | -10.00M | 0 |
| Ending cash balance | 76.32M | 22.52M | 30.37M | 18.89M | 24.46M | 32.79M | 56.75M | 40.64M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -893.00K | 30.54M | 24.03M | 21.98M | 2.73M | 30.65M |
| Depreciation & amortization | 604.00K | 607.00K | 603.00K | 601.00K | 597.00K | 848.00K |
| Free cash flow | -893.00K | 30.54M | 24.02M | 21.99M | 2.73M | -39.69M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | -3.74M | -511.00K |
| Ending cash balance | 45.79M | 53.46M | 48.59M | 40.64M | 24.47M | 60.87M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -66.96 | -81.73 | -67.72 | -55.63 | -699.05 | -- | -- | 185.94 |
| ROA %i | -54.59 | -46.67 | -23.06 | -12.90 | -38.84 | -19.95 | 12.44 | 108.34 |
| ROIC %i | -69.05 | -58.47 | -35.50 | -19.80 | -125.01 | -- | -- | 145.62 |
| 5-year avg ROE %i | -72.52 | -78.06 | -82.23 | -74.45 | -194.22 | -- | -- | -- |
| EBIT margin %i | -163.30 | -112.26 | -26.14 | -8.34 | -45.63 | -15.59 | 14.66 | 43.89 |
| FCF / sales %i | -- | -- | -- | 3.52 | -- | -- | 17.33 | 25.71 |
| Current ratioi | 4.94 | 2.04 | 2.18 | 2.43 | 1.78 | 1.86 | 2.13 | 2.42 |
| Quick ratioi | 4.78 | 1.86 | 1.79 | 2.21 | 1.51 | 1.64 | 1.88 | 2.08 |
| Debt / assetsi | 0.00 | 24.61 | 35.41 | 18.27 | 30.95 | 51.68 | 36.57 | 10.38 |
| LT debt / equityi | -- | 53.96 | 89.54 | 68.06 | -- | -- | 1,593.92 | 5.84 |
| Interest coveragei | -- | -198.68 | -20.98 | -2.56 | -14.80 | -2.65 | 3.32 | 17.64 |
| Revenue CAGR (3Y) %i | 15.49 | 42.75 | 189.35 | 49.67 | 26.58 | 2.47 | 6.30 | 34.76 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 80.88 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | 376.09 | 220.06 | 185.94 | 174.08 | 126.90 |
| ROA %i | 24.58 | 58.38 | 59.33 | 108.34 | 107.04 | 88.46 |
| ROIC %i | -- | 119.03 | 105.21 | 145.62 | 139.28 | 106.12 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 22.66 | 39.89 | 43.22 | 43.89 | 42.99 | 33.02 |
| FCF / sales %i | 17.40 | 24.56 | 24.16 | 25.71 | 26.44 | 3.27 |
| Current ratioi | 2.20 | 2.02 | 2.28 | 2.42 | 2.62 | 1.94 |
| Quick ratioi | 1.78 | 1.71 | 1.94 | 2.08 | 2.20 | 1.58 |
| Debt / assetsi | 34.70 | 29.53 | 25.10 | 10.38 | 9.06 | 7.67 |
| LT debt / equityi | 246.65 | 46.58 | 25.95 | 5.84 | 3.81 | 0.01 |
| Interest coveragei | 5.83 | 13.80 | 16.09 | 17.64 | 18.68 | 15.74 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 09:53:13 · For reference only, not investment advice and not tailored to your situation.